Inhibition of hERG channel trafficking: an under-explored mechanism for drug-induced QT prolongation.
Yeung
Kap-Sun
KS
Bristol-Myers Squibb Research and Development, 5 Research Parkway, P.O.Box 5100, Wallingford, CT 06492, USA. kapsun.yeung@bms.com
Meanwell
Nicholas A
NA
D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005473:Fluoxetine / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D006801:Humans; D020128:Inhibitory Concentration 50; D007473:Ion Channels / Q000378:metabolism; D007654:Ketoconazole / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000378:metabolism; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000188:drug therapy; D021381:Protein Transport
D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D007473:Ion Channels; C000606913:KCNH2 protein, human; D005473:Fluoxetine; D007654:Ketoconazole